Benign Prostatic Hyperplasia
Conditions
Keywords
benign prostatic hyperplasia, multicenter randomized control clinical trial, transurethral plasmakinetic enucleation of prostate, transurethral resection of prostate
Brief summary
The study is a multicentric randomized control trial with 4-year follow-up comparing perioperative and postoperative outcomes for transurethral plasmakinetic enucleation of prostate(TUKEP) and transurethral resection of prostate(TURP). The investigators recruit patient with benign prostatic hyperplasia(BPH) as the object of study. TURP is set as control group . Meanwhile TUKEP is set as test group. Six affiliated hospitals will participate in this study. Through analyzing the perioperative and postoperative data between TUKEP group and TURP group, The investigators purpose demonstrating superiority of safety, efficacy and economic benefit in TUKEP group.
Detailed description
Benign prostatic hyperplasia (BPH) is the most common disease of middle aged and elderly people which cause urinary tract symptoms (LUTS). transurethral resection of prostate(TURP) , began to replace the traditional open surgery in 1930s, still is as the gold standard operation for surgical treatment of BPH. However, compared with the traditional open operation, TURP has the following flaws:(1), due to the incomplete resection , maximum flow rate(Qmax) after TURP is lower than Qmax after open surgery. (2), there are serious complications, such as water intoxication and hemorrhage. (3) TURP has limitation to large prostate. Transurethral plasmakinetic enucleation of prostate(TUKEP), an operation mode devised by Liu Chunxiao Team in southern medical university urology department, have offset the advantage of TURP. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way. One the one hand, TUKEP effectively solve the situation that It should repeatedly cut and stop bleeding and difficultly find the surgical capsule in TURP, which obviously reduce the rate of bleeding, prostatic capsula perforation, transurethral resection syndrome(TURS) and External sphincter injury. On the other hand, TUKEP is the minimally invasive surgery. It also achieves the effect of open surgery resolving the residual gland and reoperation post TURP. The investigators plan to setup a a multicentric randomized control trial with 4-year follow-up comparing perioperative and postoperative outcomes for TUKEP and TURP. Through analyzing the perioperative and postoperative data between TUKEP group and TURP group, The purpose demonstrating superiority of safety, efficacy and economic benefit in TUKEP group.
Interventions
PROCEDURETransurethral plasmakinetic enucleation of prostate
Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
PROCEDUREtransurethral resection of prostate
Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH.
Sponsors
Nanfang Hospital, Southern Medical University
The First Affiliated Hospital of Anhui Medical University
The First Affiliated Hospital of Nanchang University
Fourth Affiliated Hospital of Guangxi Medical University
First Affiliated Hospital of Fujian Medical University
Zhujiang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
50 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnose as BPH 2. Between 50 and 80 year-old 3. Prostate volume less than 120g 4. Meet any conditions (1). International Prostate Symptom Score (IPSS),≥12 quality of life score (QOL) ≥4分 (2).Maximum urinary flow rate (Qmax) 15 ml/s or less (urine flow more than 150 ml) (3).Medication is not efficient (4).Repeated urinary retention (extubation failure more than one) (5).Schafer≥grade 2 5. The American association of anesthesia score (ASA) class 1 to 3 6. Sign the informed consent voluntarily and will be willing to follow-up
Exclusion criteria
1. Combined with central nervous system lesions (such as cerebrovascular accident, Parkinson, multiple sclerosis, cauda equina injury, spinal cord lesions, etc.) and neurogenic bladder; 2. The combination of advanced malignant tumor or chronic wasting disease; 3. Patients with severe cardiopulmonary disease or severe mental disorders; 4. Acute urinary tract infection, urethral stricture; 5. There is a history of prostate and bladder surgery; 6. Combined with severe coagulopathy; 7. Postoperative pathology confirmed prostate cancer; 8. Poor compliance, and can not be followed up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Qmax(Maximum urinary flow rate) | 4 years | Maximum urinary flow rate was measured at 1, 3, 6, 12, 24, 36 and 48-month postoperatively |
| IPSS (International Prostate Symptom Score ) | 4 years | International Prostate Symptom Score was measured at 1, 3, 6, 12, 24, 36 and 48-month postoperatively |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Operation time | up to 24 hours | operation time |
| Postoperative hospital stay | 1 month | Postoperative hospital stay |
| Indwelling catheter time | 1 month | The time of indwelling catheter post-operation |
| Postoperative irrigation | 1 month | The time of Postoperative irrigation |
| Decrease in Haemoglobin in 24 hours post-operation | 1 month | Compared with the baseline, to demonstrate the blood loss during operation |
| QOL(Quality of Life) | 4 years | The Quality of Life Score was measured at 1, 3, 6, 12, 24, 36 and 48-month postoperatively |
| Prostate-specific antigen(PSA) | 4 years | To compare the Prostate-specific antigen between TUKEP and TURP at baseline, 1,3,6,12, 24,36 and 48-month follow-up visits. |
| Hospitalization expenses | 1 month | Total costs for BPH treatment during Hospitalization. The cost of other diseases should be excluded |
| Prostate volume | 4 years | Prostate volume is measured by ultrasound or MRI at the baseline, 1,3,6,12, 24,36 and 48-month follow-up visits |
| Residual urine volume | 4 years | Residual urine in the bladder after urination(via abdominal ultrasonography) is measure at the baseline, 1,3,6,12, 24,36 and 48-month follow-up visits |
| Claviendindo classification | 4 years | It is a grade for evaluating surgical complications at 1,3,6,12, 24,36 and 48-month follow-up visits |
| Retreatment rate | 4 years | The ratio of patient who need reoperation to remove urinary tract obstruction |
| International Index Of Erectile Function (IIEF-5) | 4 years | International Index Of Erectile Function is a patient reporting outcomes measuring the erectile function at the baseline, 1,3,6,12, 24,36 and 48-month follow-up visits postoperatively. |
Countries
China
Contacts
Primary ContactShaobo Zheng, M.D
Backup ContactChunXiao Liu, M.D., Ph.D
Outcome results
None listed